Sun Pharmaceutical Industries Share Price
13 Oct, 2026 3:50 PM (IST)
Sun Pharmaceutical Industries Performance
- Today's Low
- ₹1,751
- Today's High
- ₹1,771
- 52 Week Low
- ₹1,584
- 52 Week High
- ₹2,047
- Open Price₹1,760
- Previous Close₹1,760
- Volume1,219,129
- 50 DMA₹1,853.90
- 100 DMA₹1,855.20
- 200 DMA₹1,822.60
Sun Pharmaceutical Industries Chart
Investment Returns
- Over 1 Month -3.77%
- Over 3 Month -8.51%
- Over 6 Month + 7%
- Over 1 Year + 5.97%
Smart Investing Starts Here Start SIP with Sun Pharmaceutical Industries for Steady Growth!
Sun Pharmaceutical Industries Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 35.1
- PEG Ratio
- 2.1
- Market Cap Cr
- 424,850
- P/B Ratio
- 4.9
- Average True Range
- 31.6
- EPS
- 50.4
- Dividend Yield
- 0.9
- MACD Signal
- -33.3
- RSI
- 36.68
- MFI
- 31.5
Latest Stock News Updates
Update on Credit Ratings
- BSE India
- 8 hours 2 minutes ago
Sun Pharmaceutical Industries has said its board of directors has approved a proposal to raise funds of up to Rs 10,000 crore through the issuance of non-convertible debentures (NCDs). The decision was taken at a meeting of the company's Board of Directors held on October 12, Sun Pharma said in a regulatory filing late on Monday evening. The board approved the issuance of listed, rated, unsecured, redeemable NCDs on a private placement basis in one or more tranches and/or series for an aggregate amount not exceeding Rs 10,000 crore. The company said that disclosures required under Regulation 30 of the Sebi (Listing Obligations and Disclosure Requirements) Regulations, 2015, will be made at an appropriate stage upon the issuance or allotment of the debentures. Separately, the company announced that Gautam Doshi has resigned as a Non-Executive, Independent Director with immediate effect, citing personal reasons. Consequent upon his resignation, he has also ceased to hold positions on
- Business Standard
- 11 hours 21 minutes ago
Outcome of the Board Meeting held on 12 October 2026
- BSE India
- 1 day 5 hours ago
Sun Pharmaceutical Industries Financials
Sun Pharmaceutical Industries Technicals
EMA & SMA
- Bearish Moving Average 15
- Bullish Moving Average 1
- 20 Day
- ₹1,814.60
- 50 Day
- ₹1,853.90
- 100 Day
- ₹1,855.20
- 200 Day
- ₹1,822.60
Resistance and Support
- R3 1,797.50
- R2 1,784.10
- R1 1,777.40
- S1 1,757.30
- S2 1,743.90
- S3 1,737.20
Sun Pharmaceutical Industries Corporate Actions - Bonus, Splits, Dividends
Sun Pharmaceutical Industries F&O
About Sun Pharmaceutical Industries
Active Pharma Ingredients (APIs) & variety of branded & generic formulations are produced, developed, & marketed by Sun Pharmaceuticals Industries Ltd. With global presence in trading & other ancillary activities, the corporation & its subsidiaries operate multiple manufacturing facilities across the globe, catering to the global market. It is India's biggest pharmaceutical corporation. Product Offerings: company manufactures a wide range of specialty & generic medications to address a variety of acute & chronic medical conditions. Generics, branded generics, specialist, hard-to-make technology-intensive pharmaceuticals, antiretrovirals, APIs, & intermediates are all part of its product line. It provides medications in every possible dose form, including liquids, tablets, sprays, ointments, creams, injectables, & capsules.
Indian Branded Generics: Largest Pharma business in India with 8.3% market share; Approximately 32% of revenues in FY23. Prescriptions with 12 classes of prescribers rank it first as well. In India, Sun Pharma leads the market in the chronic category. In India's top 300 pharmaceutical brands, it has 32 brands. Among other specialties, gastroenterology makes up 12%, neuropsychiatry 16%, & cardiology 18%.
US Business (~31% of revenues): This company ranks second in the US dermatology industry by prescriptions & joined the US pharma market in 1997. In terms of US generics, it ranks tenth. There were 616 ANDAs & 67 NDAs filed as of Q1FY24, & 519 ANDAs & 54 NDAs that had been authorized for a variety of therapies.
13 NDAs & 97 ANDAs are awaiting USFDA clearance. OTC, generics, & specialty markets are areas where corporations are well-represented. Liquids, creams, ointments, gels, sprays, injectables, tablets, capsules, drug-device combinations, & other products are sold by the company.
- NSE Symbol
- SUNPHARMA
- BSE Symbol
- 524715
- ISIN
- INE044A01036
Similar Stocks to Sun Pharmaceutical Industries
Popular Stocks
Sun Pharmaceutical Industries FAQs
Sun Pharmaceutical Industries share price is ₹1,770 As on 14 October, 2026 | 01:41
The Market Cap of Sun Pharmaceutical Industries is ₹424850.2 Cr As on 14 October, 2026 | 01:41
The P/E ratio of Sun Pharmaceutical Industries is 35.1 As on 14 October, 2026 | 01:41
The PB ratio of Sun Pharmaceutical Industries is 4.9 As on 14 October, 2026 | 01:41
The 52 week High & Low of Sun Pharmaceutical Industries is ₹2046.9/₹1583.7 respectively As on 14 October, 2026 | 01:41
Sun Pharmaceutical Industries (Sun Pharma) has an operating revenue of INR 36,704.43 Cr. on a trailing 12-month basis. Annual revenue growth of 3% is not great, Pre-tax margin of 8% is okay. Institutional holding has gone up in the last reported quarter is a positive sign. Analyst Recommendation on Sun Pharmaceutical Industries (Sun Pharma): HOLD
Dilip Shanghvi is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma).
The ROE of Sun Pharmaceutical Industries (Sun Pharma) is 6% which is fair but needs improvement.
Sun Pharmaceutical Industries (Sun Pharma) has a reasonable debt to equity of 2%, which signals a healthy balance sheet.
The PE ratio of Sun Pharmaceutical Industries (Sun Pharma) is 81.5.
Metrics for analyzing sun pharma share price include: P/E Ratio, ROE, Profit Growth, as it Shows historical earnings growth.
To buy Sun Pharmaceuticals Industries Ltd shares, open a 5paisa account, fund it, search for Sun Pharmaceuticals Industries Ltd , place buy order, & confirm.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.